您好,欢迎来到皮书数据库!
您现在所在的位置:首页
更多>> 课题组动态
更多>> 皮书作者
王伟光
    男,汉族,1950年2月出生,山东海阳人。1967年11月参加工作,1972年11月加入中国共产党,博士研究生学... 详情>>
李 扬
    1951年9月出生,籍贯安徽,1981年、1984年、1989年分别于安徽大学、复旦大学、中国人民大学获经济学学... 详情>>
李培林
    男,山东济南人。博士,研究员,中国社会科学院副院长,中国社会学会副会长,中国社会科学院社会学研究所副所长。《社会... 详情>>

    基本药物招标采购现状分析

    摘要

    作为新医改的重要组成部分,我国基本药物制度实施已走过3个春秋。从15省市发布的招标结果来看,基本药物招标体现一定的集中度,部分企业专注于基本药物的供应保障。虽然500强企业中标品规接近50%,但中小企业数量占绝大多数。继安徽省之后,全国各地实施基本药物招标采购均采取大幅降价策略。在生产成本日益上升的今天,药品招标大幅降价势必拷问产品质量,药品安全问题不容忽视。低于成本投标已违反国家相关法律规定,应引起各有关部门的重视并采取适当的整治措施。“十二五”期间,基本药物制度将在县级以上医疗机构实施,卫生部也提出2012年将发布新修订的基本药物目录。基层用药匮乏、不合理用药现象能否缓解,让我们拭目以待。 <<
    >>

    Abstract

    Essential Drugs System has putted into practice for three years,as an important component of the New- Healthcare Reform.It has displayed a certain extent concentration ratio discerning from the essential drugs procurement tender results published by these fifteen provinces,and some enterprises focus on the security of supply.The majority suppliers are those Small and Medium Enterprises,though half quantities of drug specifications bidding belong to the Top-500 Enterprises.It has taken a substantial price reduction strategy in the implementation of the essential drugs procurement tenders in many places after an'hui province,and the price reduction trend also being intensified.It may be influencing the quality of drugs,while reducing drug prices significantly in bidding,the production costs also rising.The drug safety can't be ignored.The phenomenon of the bidding less than the production costs which has violated the state lows are still appearing,it should attract the attention of the relevant government departments and take appropriate remediation measures.In the period of the "Twelfth Five-Year",Essential Drugs System will be implemented in medical institutions of the county level and above,the Ministry of Health of P.R.C also proposed to amend and publish the new essential drugs list in 2012.Lack drugs for primary treatment,irrational use of drugs,we can wit these phenomenon's can be alleviated or no in the future. <<
    >>
    作者简介
    邓茂:北京秦脉医药咨询有限责任公司,联系方式是dengmao@chnmed.com.cn
    陈哲峰:
    王波:对外经济贸易大学国际关系学院院长助理、 副教授、 国际低碳经济研究所常务副所长,研究领域为气候变化外交、 低碳产业发展与低碳技术转移
    <<
    >>
    相关报告